Press Releases

Companies press releases

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

May 03, 2019, 16:30 ET CRANBURY, N.J., May 3, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its […]

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019 Read More »

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

Study Met All Primary and Secondary Endpoints PL-8177 is a Melanocortin Receptor 1 Agonist Apr 04, 2019, 07:30 ET CRANBURY, N.J., April 4, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced positive

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases Read More »

Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update

Teleconference and Webcast to be held on February 12, 2019 CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems for the treatment of diseases with significant unmet medical need and

Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update Read More »

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019

CRANBURY, N.J., Feb. 6, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2019 operating results on Tuesday, February 12, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 12,

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019 Read More »

Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

Teleconference and Webcast to be held on November 13, 2018 CRANBURY, N.J., Nov. 13, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems for the treatment of diseases with significant unmet medical need and

Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update Read More »

Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

Oral Formulation Clinical Data Currently Anticipated by Year End Nov 08, 2018, 07:30 ET CRANBURY, N.J., Nov. 8, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced Phase 1, first-in-human results of

Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist Read More »

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018

Nov 07, 2018, 16:15 ET CRANBURY, N.J., Nov. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018 Read More »

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J., Sept. 13, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results Read More »

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

Sep 07, 2018, 16:00 ET CRANBURY, N.J., Sept. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018 Read More »

Palatin Technologies Added to Russell 3000® Index

Jun 25, 2018, 04:56 ET CRANBURY, N.J., June 25, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has been added to the Russell 3000® Index as part of the annual

Palatin Technologies Added to Russell 3000® Index Read More »

Scroll to Top